Arcellx

Yahoo Finance • last month

Leading Multiple Myeloma Results Unveiled at ASH 2025: Paradigm-Shifting Data Redefines Treatment Landscape | DelveInsight

ASH Annual Meeting and Exposition leaves the oncology community buzzing over a series of late-breaking presentations that experts are calling 'unprecedented.' Major pharmaceutical developers such as Johnson & Johnson, Arcellx, Gilead, Bris... Full story

Yahoo Finance • last month

Assessing Arcellx (ACLX) Valuation Following Positive Pivotal CAR T Data and Commercial Launch Plans

Arcellx (ACLX) just put fresh Phase 2 iMMagine-1 data for its multiple myeloma CAR T, anitocabtagene autoleucel, on the table, and the results look clinically meaningful for both patients and shareholders. See our latest analysis for Arce... Full story

Yahoo Finance • 2 months ago

Arcellx Enters Oversold Territory (ACLX)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the R... Full story

Yahoo Finance • 2 months ago

CAR T-cell Therapy Market Forecasts Indicate Strong Growth Trajectory in the 7MM During the Forecast Period (2025-2034) | DelveInsight

The dynamics of the CAR T-cell therapy market are anticipated to change due to the extensive R&D activities, an increase in investment for research and development of the new CAR T-cell therapy, such as zamtocabtagene autoleucel (Miltenyi... Full story

Yahoo Finance • 5 months ago

Biotech sector slips amid reported return of ousted FDA official

[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images Shares of several biotech firms fell in premarket trading Monday after reports that ousted U.S. Food and Drug Administration vaccine regulator Vinay Prasad w... Full story

Yahoo Finance • 7 months ago

Citi initiates coverage on biotech amid improving sentiment in sector

Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor interest. The brokerage launched with... Full story

Yahoo Finance • 10 months ago

Arcellx CMO Discusses Novel Investigational CAR-T Therapy During Multiple Myeloma Awareness Month

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Today's Marketplace (TMP) is proud to announce a featured interview with Arcellx, Inc. (NASDAQ: ACLX) Chief Medical Officer Christopher Heery, M.D., and Jessica Clark, DNP, RN, Dean of the Col... Full story

Yahoo Finance • 2 years ago

ARCELLX AND KITE ANNOUNCE EXPANSION IN STRATEGIC PARTNERSHIP

-- Arcellx to receive $200M equity investment at $61.68 per share and an $85 million upfront cash payment -- -- Kite exercises option to Arcellx's ARC-SparX program ACLX-001 in multiple myeloma -- -- The companies expand the scope of the... Full story

Yahoo Finance • 2 years ago

Kite and Arcellx Announce Expansion in Strategic Partnership

-- The companies expand the scope of their existing collaboration for CART-ddBCMA to include lymphomas -- -- Kite exercises option to Arcellx’s ARC-SparX program ACLX-001 in multiple myeloma -- -- Arcellx to receive $200M equity investme... Full story

Yahoo Finance • 3 years ago

Gilead to co-develop Arcellx's multiple myeloma drug

Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcellx $225 million upfront, plus make a $10... Full story

Yahoo Finance • 3 years ago

‘The bear market rally has more room to run,’ Guggenheim Says. Here are 2 stocks to bet on

The October inflation numbers came out last week, and sparked solid gains in the markets. Investors were buoyed by better-than-expected price data when the Bureau of Labor Statistics’ Consumer Price Index came in at 7.7% annualized. This w... Full story